Allisone has raised €10 million to use AI to improve oral health care
On September 5, 2022, the west Paris startup, Allisone, completed a €10 million financing round
led by venture capital company C4 Ventures, with the participation of the Spanish fund Samaipata.
Created in 2021, Allisone has developed a diagnosis and treatment display platform that facilitates
communication between dental surgeons and their patients. Its software automatically analyzes
dental panoramas and can detect a cavity, a lesion or an implant, using color codes. It also helps
draft a report and implement the care protocol.
This funding should enable 3,000 dentists throughout Europe to make use of this solution (at the
moment slightly more than 1,000) by the end of the year. 50 people are currently being recruited.
Apmonia Therapeutics has raised €2.5 million to treat solid cancers
Apmonia Therapeutics is developing a pipeline of peptide-based drug candidates targeting the
tumor microenvironment and offering new therapeutic perspectives in oncology. On September 6,
2022, it obtained €2.5 million in the context of the Bpifrance Deep Tech plan. This funding will be
used to accelerate its R&D programs and consolidate the initial very encouraging results achieved
since the company was established (in 2019, in Reims), with a view to the industrial development of
its peptides and an initial clinical trial authorization.
In February 2022, the company had already raised €4 million. It has, therefore, raised a total of over
€8 million to allow it to develop its Drug Discovery platform.
SiVIEW, the AI specialist in the service of visual health, has raised €5.5 million
The startup, founded in 2016, has created software that uses AI to automate eye examinations at the
opticians and ophthalmologists. SiviewExam® is compatible with almost all optical equipment
available on the market and provides complete results in under 8 minutes (measurements and
report). The eye examination is faster and more precise thus supporting diagnosis and prescription.
Announced on September 13, this series A was carried out with the Digital Health 2 sector fund of
LBO France and will allow the startup to expand its international operations, on the North
American and Asian markets, and to invest in its R&D.
SparingVision : €75 million to finance two Human clinical trials for the treatment of retinitis
pigmentosa
SparingVision announced on September 14 that it has raised €75 million in a series B financing, led
by Jeito Capital and UPMC Entreprises, with the participation of 4BIO Capital, Bpifrance, the RD
Fund and Ysios Capital. Its previous €44.5 million fundraising was back in October 2020.
SparingVision, a spin-off from the Institut de la Vision, in Paris, was launched in 2016.
This operation will serve to finance two Human trials of two treatments against retinitis pigmentosa
(RP), SPVN06 and SPVN20. They are aimed at reducing or even stopping the progress of this
genetic disorder, which affects two million people worldwide. Initial results are expected for 2025.
Incepto has raised €27 million to expand its presence in Europe
Created in January 2018, Incepto has developed a platform that offers medical personnel a range of
AI-based services, to save them time and improve diagnostics. This financing round of €27 million,
announced on September 20, 2022, was led by LBO France, with the participation of Wille Finance
and its historic investors AXA Venture Partners (AVP), the Bpifrance Patient Autonome fund and
Karista. Incepto is launching four new subsidiaries in Europe, in Germany, Spain, Italy and
Portugal. The startup also announced the signature of five new partnerships (IBlab, Milvue, PAIRE,
Smartsoft and Thirona) which have expanded its bouquet of applications in medical imaging,
emergency care, oncology, orthopedics, rheumatology and pneumology.
The Paris-based firm presents itself as “the Netflix of medical imaging”. Its aim is to treat a million
patients a month in Europe by 2024.
Quinten has raised €14 million to launch two new healthcare data operating software
programs
On September 20, Quinten made public a €14 million financing round led by the Techlife Capital
investment fund and the Mutuelle d’assurance du corps de santé français (MACSF).
Quinten is a data science and artificial intelligence business founded in 2008. It aims to invest this
capital in the development of two new software programs intended for pharmaceutical laboratories
and pharmacists, in order to initially accelerate the discovery of drugs via reference disease
modeling using real-life data. The second product allows hospital-based pharmacists to provide
secure prescriptions.
Pherecydes Pharma has raised €3.1 million to fight against resistance to antibiotics
On September 22, 2022, Pherecydes Pharma, the specialist in precision phagotherapy designed to
treat bacterial infections that are complicated and/or resistant to antibiotics, announced an increase
in capital of €3.1 million, €2.6 million of which came from institutional investors and €0.5 million
from private individuals (via the PrimaryBid platform). The proceeds from this fundraising will be
used, among other things, to finance the clinical development of anti-Staphylococcus aureus phages
for the Phase II PhagoDAIR study, in France and in Europe, with the opening of new clinical
centers, notably in Spain and the Netherlands. It will also help launch another Phase II study in a
clinical indication with substantial medical needs and fund the development of anti-Pseudomonas
aeruginosa phages. Pherecydes Pharma was founded in Nantes, in 2006.
Vetbiolix has raised €2.5 million to develop drug candidates for dogs and cats
The company, which has been awarded the French Tech Seed label, announced on September 26 a
seed financing round of €2.5 million bringing together the two investment funds CapTech Santé and
Nord France Amorçage, BPI France, and a pool of Business Angels in the veterinary domain. This
fundraising will facilitate the clinical development of its pipeline of drug candidates, medical
devices and innovative care products for dogs and cats suffering from pathologies with medical
needs that are not being met (periodontal, chronic inflammatory, gastrointestinal, dermatological
diseases, cancer and related pathologies). The company was founded in 2018 in the Lille
metropolitan area.
BioMAdvanced Diagnostics has raised €1.7 million to reduce kidney and lung transplant rejections
Established in 2021 in Nantes, the startup develops solutions that identify biomarkers to assess, plan
and diagnose the risk of rejection of renal and pulmonary transplants and adapt treatments. The
fundraising, announced on September 27, was led by Sodero Gestion, with Pays de la Loire
Participations, Atlantique Vendée Innovation (investment fund Crédit Agricole Atlantique Vendée),
SATT Ouest Valorisation and Bpifrance, notably via the French Tech Seed fund.
The operation will allow BioMAdvanced Diagnostics to finalize the design of its first products and
to initiate two clinical studies, one into the rejection of kidney transplants, the other being a study of
the lungs. The clinical study into the kidney rejection test will be carried out in partnership with the
University Hospital of Nantes, the University Hospital of Oslo and the University Hospital of
Barcelona with 300 transplanted patients and will allow the application for CE marking for a
marketing launch planned in 2025.
